An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Greenbrook TMS Inc. (NASDAQ: GBNH) announced the immediate resignation of Roberto Drassinower as Chief Operating Officer, who will continue as an advisor under a consulting agreement. Mr. Drassinower expressed enthusiasm for supporting the company's growth strategy while prioritizing family time. Greenbrook operates 149 treatment centers, providing Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder, having delivered over 730,000 treatments to 20,000 patients. The company highlights its commitment to mental health with a focus on future growth.
Positive
Continued advisory support from Roberto Drassinower may ensure stability during leadership transition.
Greenbrook has a robust operational foundation with 149 treatment centers and a commitment to TMS therapy.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”) announced today that Roberto Drassinower will be stepping down from his role as Chief Operating Officer of the Company, effective immediately, but will continue to provide advisory services to the Company pursuant to the terms of a consulting agreement with the Company.
Mr. Drassinower commented: “I am excited to continue supporting Greenbrook and Bill Leonard in our growth strategy for the business while being able to take time to spend with my family.”
About Greenbrook TMS Inc.
Operating through 149 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 730,000 TMS treatments to over 20,000 patients struggling with depression.
Cautionary Note Regarding Forward-Looking Information
Certain information in this press release constitutes forward-looking information within the meaning of applicable securities laws in Canada and the United States, including the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the factors described in greater detail in the “Risk Factors” section of the Company’s current annual information form, in the “Risks and Uncertainties” section of the Company’s current management’s discussion and analysis and in the Company’s other materials filed with the Canadian securities regulatory authorities and the United States Securities and Exchange Commission from time to time, available at www.sedar.com and www.sec.gov, respectively. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
